Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue HemaSphere Année : 2022

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma

Domaines

Hématologie

Dates et versions

hal-03737664 , version 1 (25-07-2022)

Identifiants

Citer

Olivier Tournilhac. Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma. HemaSphere, 2022, 6 (2), pp.e675. ⟨10.1097/HS9.0000000000000675⟩. ⟨hal-03737664⟩
22 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More